MCID: SYS045
MIFTS: 18

Systemic Lupus Erythematosus 14

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 14

MalaCards integrated aliases for Systemic Lupus Erythematosus 14:

Name: Systemic Lupus Erythematosus 14 54
Systemic Lupus Erythematosus, Susceptibility to, 14 13

Classifications:



External Ids:

OMIM 54 613145

Summaries for Systemic Lupus Erythematosus 14

MalaCards based summary : Systemic Lupus Erythematosus 14, is also known as systemic lupus erythematosus, susceptibility to, 14. An important gene associated with Systemic Lupus Erythematosus 14 is SLEB14 (Systemic Lupus Erythematosus, Susceptiblity To, 14). The drugs Cyclophosphamide and belimumab have been mentioned in the context of this disorder. Affiliated tissues include testes, bone and kidney.

Description from OMIM: 613145

Symptoms & Phenotypes for Systemic Lupus Erythematosus 14

Clinical features from OMIM:

613145

Drugs & Therapeutics for Systemic Lupus Erythematosus 14

Drugs for Systemic Lupus Erythematosus 14 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 2 50-18-0, 6055-19-2 2907
2
belimumab Approved Phase 4,Phase 3,Phase 2 356547-88-1 5957 10451420
3 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 2,Phase 3
4 Vaccines Phase 4,Phase 2,Phase 3
5 Immunoglobulins Phase 4,Phase 3,Phase 2
6 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
7 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
8 Antibodies Phase 4,Phase 3,Phase 2
9 Autoantibodies Phase 4
10 Anti-Inflammatory Agents, Non-Steroidal Phase 4
11 Antimalarials Phase 4
12 Neurotransmitter Agents Phase 4,Phase 3
13
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
14
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
15
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
16
Acetaminophen Approved Phase 3 103-90-2 1983
17
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
18
Diphenhydramine Approved Phase 3 58-73-1, 147-24-0 3100
19
Promethazine Approved Phase 3 60-87-7 4927
20 Prednisolone acetate Phase 3,Phase 2
21 Analgesics Phase 3
22 glucocorticoids Phase 3,Phase 2
23 Methylprednisolone acetate Phase 3,Phase 2
24 Methylprednisolone Hemisuccinate Phase 3,Phase 2
25 Gastrointestinal Agents Phase 3,Phase 2
26 Neuroprotective Agents Phase 3,Phase 2
27 Analgesics, Non-Narcotic Phase 3
28 Hormone Antagonists Phase 3,Phase 2
29 Hormones Phase 3,Phase 2
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
31 Peripheral Nervous System Agents Phase 3,Phase 2
32 Antibodies, Monoclonal Phase 3,Phase 2
33 Prednisolone hemisuccinate Phase 3,Phase 2
34 Prednisolone phosphate Phase 3,Phase 2
35 Antiemetics Phase 3,Phase 2
36 Protective Agents Phase 3,Phase 2
37 Autonomic Agents Phase 3,Phase 2
38 Antirheumatic Agents Phase 3,Phase 2
39 Antineoplastic Agents, Hormonal Phase 3,Phase 2
40
Histamine Phosphate Phase 3 51-74-1 65513
41 Central Nervous System Depressants Phase 3
42 Histamine Antagonists Phase 3
43 Histamine H1 Antagonists Phase 3
44 Anesthetics Phase 3
45 Dermatologic Agents Phase 3
46 Anesthetics, Local Phase 3
47 Anti-Allergic Agents Phase 3
48 Hypnotics and Sedatives Phase 3
49 Pharmaceutical Solutions Phase 3
50 Antipruritics Phase 3

Interventional clinical trials:

(show all 34)

id Name Status NCT ID Phase Drugs
1 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
2 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
3 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT01632241 Phase 4 Standard therapy
4 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
5 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4 Milnacipran
6 Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus Completed NCT00611663 Phase 2, Phase 3
7 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT00424476 Phase 3 Placebo;Belimumab 1 mg/kg;Belimumab 10 mg/kg
8 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus Completed NCT00410384 Phase 3 Placebo;Belimumab 1 mg/kg;Belimumab 10 mg/kg
9 A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus Terminated NCT02041091 Phase 3 Tabalumab Auto-Injector;Tabalumab Prefilled Syringe
10 A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus Terminated NCT00381810 Phase 3 Rituximab;Methylprednisolone;Acetaminophen;Diphenhydramine
11 Study of LJP 394 in Lupus Patients With History of Renal Disease Terminated NCT00089804 Phase 3 abetimus sodium (LJP 394) and/or placebo solution;abetimus sodium (LJP 394);Phosphate-buffered saline
12 A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus Completed NCT01283139 Phase 2
13 Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects Completed NCT01534403 Phase 2
14 Vitamin D3 in Systemic Lupus Erythematosus Completed NCT00710021 Phase 2 Vitamin D3;Vitamin D3 placebo
15 Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus Completed NCT00556192 Phase 2 rituximab
16 Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors Completed NCT00519363 Phase 1, Phase 2 atorvastatin
17 Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT00071487 Phase 2 Placebo;Belimumab 1 mg/kg;Belimumab 4 mg/kg;Belimumab 10 mg/kg
18 A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus. Completed NCT01031836 Phase 2 MEDI-545;MEDI-545;MEDI-545;MEDI-545;MEDI-545;MEDI-545 600
19 Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone Completed NCT00119678 Phase 2 Abatacept;Placebo;Prednisone;Abatacept
20 Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome Completed NCT01160666 Phase 2 Belimumab
21 Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Active, not recruiting NCT02265744 Phase 2 BMS-931699;Placebo matching BMS-931699
22 Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE) Terminated NCT00732940 Phase 2 Belimumab 100 mg SC;Belimumab 100 mg SC
23 Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant Terminated NCT01025193 Phase 2 Belimumab
24 Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE Withdrawn NCT01702038 Phase 2 Rituximab
25 A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184 Completed NCT01953835 Phase 1 GSK2586184 standard formulation;Simvastatin;Rosuvastatin;GSK2586184 new formulation
26 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus Completed NCT02106897 Phase 1 BIIB059;Placebo
27 A Phase I Study of ICP-022 in Subjects Recruiting NCT03189017 Phase 1 ICP-022;Placebos
28 Aerobic Exercise in Women With Systemic Lupus Erythematosus Not yet recruiting NCT03186794 Phase 1
29 Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE) Completed NCT02006784
30 Low-dose IL-2( Interleukin-2) Treatment in SLE Completed NCT02084238 Interleukin-2
31 A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies Completed NCT01858792 Belimumab 1 mg/kg;Belimumab 10 mg/kg
32 International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus Completed NCT01509989
33 Accuracy, Feasibility and Acceptance of CGM Lupus Recruiting NCT03296995
34 Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus Recruiting NCT00582881

Search NIH Clinical Center for Systemic Lupus Erythematosus 14

Genetic Tests for Systemic Lupus Erythematosus 14

Anatomical Context for Systemic Lupus Erythematosus 14

MalaCards organs/tissues related to Systemic Lupus Erythematosus 14:

39
Testes, Bone, Kidney, T Cells, B Cells

Publications for Systemic Lupus Erythematosus 14

Variations for Systemic Lupus Erythematosus 14

Expression for Systemic Lupus Erythematosus 14

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 14.

Pathways for Systemic Lupus Erythematosus 14

GO Terms for Systemic Lupus Erythematosus 14

Sources for Systemic Lupus Erythematosus 14

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....